

Final - February 25, 2019

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium

Atlanta, Georgia 30329

February 27-28, 2019

AGENDA ITEM

PRESIDER/PRESENTER(S)

Wednesday, February 27

| | | |
|--------------|---|---|
| 8:00 | Welcome & Introductions | Dr. Jose Romero (ACIP Chair) Dr. Amanda Cohn (ACIP Executive Secretary; CDC) |
| 8:20 | Japanese Encephalitis Vaccine | |
| | Introduction | Dr. Chip Walter (ACIP, WG Chair) |
| | Background and review | Dr. Susan Hills (CDC/NCEZID) |
| | Updated recommendations for U.S. travelers | Dr. Susan Hills (CDC/NCEZID) |
| | Accelerated primary series in adults | Dr. Susan Hills (CDC/NCEZID) |
| | Booster dose recommendations | Dr. Susan Hills (CDC/NCEZID) |
| 9:20 | Break | |
| 9:30 | Anthrax Vaccines | |
| | Introduction | Dr. David Stephens (ACIP, WG Chair) |
| | AV7909 (NuThrax) | Dr. William Bower (CDC/NCEZID) |
| | Preexposure AVA booster dose interval | Dr. William Bower (CDC/NCEZID) |
| 10:30 | Break | |
| 10:40 | Influenza Vaccines | |
| | Introduction | Dr. Chip Walter |
| | Surveillance update | Ms. Lynnette Brammer (CDC/NCIRD) |
| | VE update | Dr. Brendan Flannery (CDC/NCIRD) |
| | Afluria quadrivalent for children aged 6 through 59 months | Dr. Gregg Sylvester (Seqirus) |
| | Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink | Dr. James Donahue (Marshfield Clinic) |
| | Summary and work group considerations | Dr. Lisa Grohskopf (CDC/NCIRD) |
| 12:00 | Lunch | |
| 1:00 | Human Papillomavirus Vaccines | |
| | Introduction | Dr. Peter Szilagyi (ACIP, WG Chair) |
| | Overview and background | Dr. Lauri Markowitz (CDC/NCIRD) |
| | Impact and cost effectiveness of mid-adult HPV vaccination | Dr. Marc Brisson (Laval University) |
| | Overview of health economic results from 4 modeling groups | Dr. Harrell Chesson (CDC/NCHHSTP) |
| | Mid-adult HPV vaccination: patient values and acceptability | Dr. Nancy McClung (CDC/NCIRD) |
| | Program and vaccine provider surveys | Dr. Elissa Meites (CDC/NCIRD) |
| | Work group considerations | Dr. Lauri Markowitz (CDC/NCIRD) |
| 2:30 | Break | |
| 2:40 | Combination Vaccines | |
| | Introduction | Dr. Kelly Moore (ACIP, WG Chair) |
| | Immunogenicity and safety of a pediatric hexavalent vaccine | Dr. Andrew Lee (Merck) |
| | Hib vaccines in AI/AN population | Dr. Laura Hammitt (Johns Hopkins University) |
| | Summary, review of work group considerations | Dr. Sara Oliver (CDC/NCIRD) |
| 3:30 | Break | |
| 3:40 | Public Comment | |
| 4:55 | Break | |
| 5:00 | VOTES | |
| | Japanese Encephalitis Vaccine | Dr. Susan Hills (CDC/NCEZID) |
| | Anthrax Vaccines | Dr. William Bower (CDC/NCEZID) |
| 5:30 | Adjourn | |

Final - February 25, 2019

Thursday, February 28

| | | |
|--|--------------|---|
| 8:00 Agency Updates & Unfinished Business | | Dr. Nancy Messonnier (CDC/NCIRD); <i>Ex Officio</i> Members |
| CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO | | |
| 8:30 Pneumococcal Vaccines | | |
| Introduction | | Dr. Grace Lee (ACIP, WG Chair) |
| PCV13 direct and indirect effects on serotype 3 disease | | Dr. Tamara Pilishvili (CDC/NCIRD) |
| PCV13 direct effects on pneumonia hospitalizations in adults | | Dr. Fernanda Lessa (CDC/NCIRD) |
| Comparison of economic analyses of PCV13 use among adults ≥65 years old | | Dr. Andrew Leidner (CDC/NCIRD) |
| GRADE and Evidence to Recommendations (EtR) for PCV13 use among adults ≥65 years old in the context of indirect effects experience to date | | Dr. Almea Matanock (CDC/NCIRD) |
| 10:30 | Break | |
| 10:40 Meningococcal Vaccines | | |
| Introduction | | Dr. David Stephens (ACIP, WG Chair) |
| Immunogenicity and safety of a MenB-FHbp booster dose | | Dr. Paul Balmer (Pfizer) |
| Immunogenicity and safety of a MenB-4C booster dose | | Dr. Phil Watson (GSK) |
| GRADE and Evidence to Recommendations Framework for MenB booster doses | | Dr. Catherine Bozio (CDC/NCIRD) |
| Work Group interpretation of data, considerations, and next steps | | Dr. Sarah Mbaeyi (CDC/NCIRD) |
| 11:55 | Lunch | |
| 1:00 Zoster Vaccines | | |
| Introduction | | Dr. Kelly Moore (ACIP, WG Chair) |
| Zoster vaccine uptake and supply | | Dr. Kathleen Dooling (CDC/NCIRD) |
| RZV safety update | | Dr. Tom Shimabukuro (CDC/NCEZID) |
| 1:40 Hepatitis Vaccines | | |
| Introduction | | Dr. Kelly Moore (ACIP, WG Chair) |
| Background: HepA vaccines and persons with HIV infection | | Dr. Mark Weng (CDC/NCHHSTP) |
| GRADE: Use of HepA vaccines among persons with HIV infection | | Ms. Alaya Koneru (CDC/NCHHSTP) |
| Evidence to Recommendation Framework: Use of HepA vaccines among persons with HIV infection | | Dr. Mark Weng (CDC/NCHHSTP) |
| 2:35 Vaccine Supply | | |
| 2:40 Adjourn | | |

Acronyms

| | |
|---------|--|
| AI/AN | American Indian/Alaska Native |
| AVA | Anthrax vaccine absorbed |
| CDC | Centers for Disease Control & Prevention |
| CMS | Centers for Medicare and Medicaid Services |
| DoD | Department of Defense |
| DVA | Department of Veterans Affairs |
| EtR | Evidence to Recommendations Framework |
| FDA | Food and Drug Administration |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| Hib | <i>Haemophilus influenzae</i> type b |
| HRSA | Health Resources and Services Administration |
| IHS | Indian Health Service |
| MenB | Serogroup B meningococcal vaccine |
| NCHHSTP | National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] |
| NCIRD | National Center for Immunization & Respiratory Diseases [of CDC/OID] |
| NCEZID | National Center for Emerging and Zoonotic Diseases [of CDC/OID] |
| NVPO | National Vaccine Program Office |
| PCV13 | 13-valent pneumococcal conjugate vaccine |
| RZV | Recombinant zoster vaccine |
| WG | Work Group |